BACKGROUND/AIMS: Patients with head and neck squamous cell carcinoma (HNSCC) are at risk for second primary malignancies (SPMs). The prevalence, distribution, and patient survival in head and neck versus non-head and neck SPMs are not fully elucidated. The objective of this study was to quantify the rate of SPMs in patients with HNSCC. METHODS: This is a population-based cohort study using the Surveillance, Epidemiology, and End Results (SEER) database. Prevalence and location of SPMs, and survival data were analyzed. RESULTS: There were 58,363 HNSCC patients, and the prevalence of HNSCC and non-HNSCC SPMs was 3.0% (1,746) and 8.8% (5,109), respectively. Overall survival (OS) was higher in patients with HNSCC SPMs compared to non-HNSCC SPMs (p < 0.001), with no difference in disease-specific survival. Patients with SPMs in the lung and esophagus had a worse OS (p < 0.001), and patients with SPMs in the prostate and breast had a better OS (p < 0.001). CONCLUSION: In HNSCC patients who develop SPMs, nearly 75% are non-HNSCC SPMs. Patients with non-HNSCC SPMs have a lower OS. Future clinical practice guidelines should take the risks and locations of SPM development into consideration for screening.
BACKGROUND/AIMS: Patients with head and neck squamous cell carcinoma (HNSCC) are at risk for second primary malignancies (SPMs). The prevalence, distribution, and patient survival in head and neck versus non-head and neck SPMs are not fully elucidated. The objective of this study was to quantify the rate of SPMs in patients with HNSCC. METHODS: This is a population-based cohort study using the Surveillance, Epidemiology, and End Results (SEER) database. Prevalence and location of SPMs, and survival data were analyzed. RESULTS: There were 58,363 HNSCC patients, and the prevalence of HNSCC and non-HNSCC SPMs was 3.0% (1,746) and 8.8% (5,109), respectively. Overall survival (OS) was higher in patients with HNSCC SPMs compared to non-HNSCC SPMs (p < 0.001), with no difference in disease-specific survival. Patients with SPMs in the lung and esophagus had a worse OS (p < 0.001), and patients with SPMs in the prostate and breast had a better OS (p < 0.001). CONCLUSION: In HNSCC patients who develop SPMs, nearly 75% are non-HNSCC SPMs. Patients with non-HNSCC SPMs have a lower OS. Future clinical practice guidelines should take the risks and locations of SPM development into consideration for screening.
Authors: Gordon H Sun; Oluseyi Aliu; Nicholas M Moloci; Joshua K Mondschein; James F Burke; Rodney A Hayward Journal: Cancer Date: 2013-09-24 Impact factor: 6.860
Authors: Shrujal S Baxi; Laura C Pinheiro; Sujata M Patil; David G Pfister; Kevin C Oeffinger; Elena B Elkin Journal: Cancer Date: 2014-02-22 Impact factor: 6.860
Authors: J S Cooper; T F Pajak; P Rubin; L Tupchong; L W Brady; S A Leibel; G E Laramore; V A Marcial; L W Davis; J D Cox Journal: Int J Radiat Oncol Biol Phys Date: 1989-09 Impact factor: 7.038
Authors: Luc G T Morris; Andrew G Sikora; Richard B Hayes; Snehal G Patel; Ian Ganly Journal: Cancer Causes Control Date: 2011-02-15 Impact factor: 2.506
Authors: Kapila Manikantan; Shailesh Khode; Raghav C Dwivedi; Rajan Palav; Chris M Nutting; Peter Rhys-Evans; Kevin J Harrington; Rehan Kazi Journal: Cancer Treat Rev Date: 2009-09-09 Impact factor: 12.111
Authors: Shu-Chun Chuang; Ghislaine Scelo; Jon M Tonita; Sharon Tamaro; Jon G Jonasson; Erich V Kliewer; Kari Hemminki; Elisabete Weiderpass; Eero Pukkala; Elizabeth Tracey; Soren Friis; Vera Pompe-Kirn; David H Brewster; Carmen Martos; Kee-Seng Chia; Paolo Boffetta; Paul Brennan; Mia Hashibe Journal: Int J Cancer Date: 2008-11-15 Impact factor: 7.396